Table 3.
Summary of response rates: all-treated population
| EOC (n = 18) | GBM (n = 33) | HCC (n = 27) | SCCHN (n = 29) | Overalla (n = 74) | |
|---|---|---|---|---|---|
| Best overall response, n (%) | |||||
| Complete responseb | 0 | 0 | 0 | 1 (3.4) | 1 (1.4) |
| Partial responseb | 1 (5.6) | 0 | 2 (7.4) | 3 (10.3) | 6 (8.1) |
| Stable disease | 6 (36.3) | 4 (12.1) | 8 (29.6) | 7 (24.1) | 21 (28.4) |
| Progressive disease | 10 (55.6) | 26 (78.8) | 14 (51.9) | 11 (37.9) | 35 (47.3) |
| Not assessablec | 1 (5.6) | 3 (9.1) | 3 (11.1) | 7 (24.1) | 11 (14.9) |
| Unconfirmed complete response | 1 (5.6) | — | 0 | 0 | 1 (1.4) |
| Unconfirmed partial response | 0 | — | 1 (3.7) | 0 | 1 (1.4) |
| Overall response, n (%) | |||||
| Responders (complete or partial response)b | 1 (5.6) | 0 | 2 (7.4) | 4 (13.8) | 7 (9.5) |
| 90% CId | 0.3-23.8 | 0.0-8.7 | 1.3-21.5 | 4.9-28.8 | 4.5-17.0 |
| Median PFS (95% CI) | 2.04 (1.91-3.94) | 1.30 (1.22-1.38) | 2.04 (1.84-4.01) | 2.10 (1.84-1.91) | 1.92 (1.81-2.04)e |
CI, confidence interval; EOC, epithelial ovarian cancer; GBM, glioblastoma; HCC, hepatocellular carcinoma; PFS, progression-free survival; SCCHN, squamous cell carcinoma of the head and neck.
Including EOC, HCC, and SCCHN cohorts, as per RECIST v1.1 criteria.
Confirmation of response was required.
Including patients with no target and non-target lesions identified at baseline and no new lesions reported in post-baseline tumor assessments, or patients with only non-target lesions identified at baseline with non-complete response/non-progressive disease reported for non-target lesion and no new lesions reported in post-baseline tumor assessments.
Estimated using the Clopper–Pearson method.
PFS estimate for all-treated population (n = 107).